RMC No. 68-2022 updates the FDA-endorsed VAT-exempt medicines list under CREATE for key disease categories including COVID-19 and cancer.

Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of medicines must check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration, because qualifying medicines for hypertension, diabetes, high cholesterol, kidney diseases, mental illnesses, tuberculosis, cancer, and COVID-19 treatment may be sold without 12% VAT under the CREATE Act framework.

What Changed Under RMC No. 68-2022

RMC No. 68-2022 publishes the April 26, 2022 letter of the Food and Drug Administration of the Department of Health, through OIC-Director General Dr. Oscar G. Gutierrez, Jr., endorsing updates to the List of VAT-Exempt Medicines under Republic Act No. 11534, otherwise known as the CREATE Act.

The core tax consequence is practical and immediate: certain medicines falling within the listed therapeutic categories may be treated as VAT-exempt, provided they are part of the FDA-endorsed updated list. This matters because the Philippines imposes a 12% value-added tax on VATable sales, but medicines expressly covered by the VAT exemption under the CREATE Act and included in the relevant FDA-endorsed list are not subject to that VAT at the point of sale.

For business owners and finance teams, the key issue is not merely whether a medicine is generally used for a covered illness. The safer compliance approach is to verify that the specific medicine is included in the applicable VAT-exempt medicines list endorsed by the FDA and published through the BIR. This is especially important for companies handling medicine pricing, billing, point-of-sale systems, invoices, official receipts, VAT returns, and input tax reporting.

Medicines Covered by the Updated VAT-Exempt List

RMC No. 68-2022 identifies the updated list as covering certain medicines prescribed for hypertension, diabetes, high cholesterol, kidney diseases, mental illnesses, tuberculosis, cancer, and COVID-19 treatment.

These categories are highly relevant to pharmacies, drugstores, hospitals, clinics, HMOs, medical distributors, e-commerce medicine platforms, and corporate taxpayers that purchase medicines for employee health programs. The covered categories also include medicines for common chronic conditions such as hypertension, diabetes, and high cholesterol, as well as high-cost and public-health-sensitive treatment categories such as cancer, tuberculosis, kidney diseases, mental illnesses, and COVID-19 treatment.

The important point for CFOs and corporate accountants is that the category alone should not be treated as a blanket VAT exemption for all products used in that disease area. The exemption depends on inclusion in the updated VAT-exempt medicines list endorsed by the FDA and published through the BIR. A taxpayer should therefore maintain product-level documentation rather than relying on general descriptions in purchase orders or pharmacy records.

Who Is Most Affected

The most directly affected taxpayers are pharmacies, drugstores, hospital pharmacies, medical clinics, pharmaceutical distributors, medicine importers, wholesalers, retailers, and other VAT-registered sellers dealing with medicines that may fall under the VAT exemption. These businesses must ensure that their sales systems correctly classify covered medicines as VAT-exempt and non-covered medicines as VATable, where applicable.

Hospitals and clinics are also affected because patient billing may include medicines with different VAT treatment from other goods or services. Billing departments should ensure that invoices, statements of account, and accounting records distinguish VAT-exempt medicines from VATable transactions.

Corporate buyers, employers, and institutional purchasers are likewise affected when they buy medicines in bulk or reimburse medicine purchases. While the seller is normally the party charging and reporting VAT on the sale, buyers should still verify whether VAT was properly excluded for medicines covered by the updated list. This may affect cost, reimbursement, procurement controls, and audit documentation.

Effective Date and Compliance Timing

RMC No. 68-2022 was issued on May 12, 2022. The FDA endorsement letter published by the circular is dated April 26, 2022. Businesses dealing in covered medicines should treat the issuance as a compliance trigger to review product classifications, update pricing and billing systems, and confirm whether covered products are being sold or purchased with the correct VAT treatment.

Because the circular publishes updates to the VAT-exempt medicines list, the most urgent business action is product-level review. Accounting teams should not wait until annual audit or tax filing season to correct VAT treatment. Misclassification can create discrepancies in sales reports, VAT returns, customer invoices, and supporting schedules for tax audits.

Key Compliance Requirements for Businesses

Businesses should first identify all products in their inventory or procurement records that are medicines prescribed for hypertension, diabetes, high cholesterol, kidney diseases, mental illnesses, tuberculosis, cancer, and COVID-19 treatment. The next step is to match those products against the updated VAT-exempt medicines list endorsed by the FDA and published under RMC No. 68-2022.

Once the covered products are identified, sellers should update their point-of-sale systems, billing templates, enterprise resource planning systems, and tax codes to ensure that qualified medicines are treated as VAT-exempt. Finance teams should also confirm that the VAT exemption is reflected in sales invoices, official receipts, books of accounts, and VAT return working papers.

For distributors and wholesalers, product master files should be reviewed carefully. A single error in product coding can cause repeated VAT errors across multiple branches, outlets, or customer accounts. For pharmacies and hospitals, front-end billing personnel should also be aligned with accounting and compliance teams so that the VAT exemption is implemented consistently.

For buyers, especially hospitals, clinics, and companies with medicine procurement programs, purchase invoices should be checked to confirm whether 12% VAT was charged on medicines that may be covered by the updated VAT-exempt list. Where VAT was charged despite apparent VAT-exempt status, the buyer should coordinate with the seller for clarification and proper documentation.

Penalties and Audit Risks for Non-Compliance

RMC No. 68-2022 itself publishes the FDA endorsement of the updated list and does not create a separate penalty provision in the summarized text. However, incorrect VAT treatment can still create tax audit exposure under general VAT, invoicing, bookkeeping, and tax return rules.

If a seller treats a VATable product as exempt without sufficient basis, the BIR may assess deficiency VAT, surcharge, interest, and compromise penalties under applicable tax rules. Conversely, if a seller charges VAT on medicines that should be VAT-exempt, the issue may result in customer disputes, pricing concerns, and accounting corrections. For regulated businesses such as pharmacies and hospitals, repeated billing errors may also create reputational and compliance concerns beyond the tax return itself.

The safest position is to maintain clear documentation showing why a medicine was treated as VAT-exempt. This includes the FDA-endorsed list, product details, internal tax classification approvals, supplier documents, and accounting system records showing when the tax treatment was implemented.

Practical Steps for CFOs, Accountants, Pharmacies, and Medical Businesses

Businesses should immediately conduct a product-level VAT review for medicines related to hypertension, diabetes, high cholesterol, kidney diseases, mental illnesses, tuberculosis, cancer, and COVID-19 treatment. The review should not be limited to product categories or marketing descriptions. It should verify whether the specific medicine appears in the updated VAT-exempt medicines list.

Accounting teams should then update VAT tax codes in their systems and ensure that the correct treatment is reflected in invoices and receipts. For businesses operating multiple branches, the head office should issue a standardized implementation memo so that branch-level cashiers, pharmacists, billing staff, and accountants apply the same tax treatment.

Procurement teams should also require suppliers to identify whether medicines being sold are VAT-exempt under the updated list. For high-volume or high-value medicine purchases, the buyer should request supporting documentation from the supplier to avoid later disputes during audit or reimbursement processing.

Tax managers should also review VAT returns filed after the relevant implementation period to identify whether any adjustments, reconciliations, or supporting schedules may be needed. Keywords commonly searched by Philippine accountants and CFOs in relation to this issuance include RMC No. 68-2022 VAT-exempt medicines, CREATE Act VAT exemption medicines, FDA list of VAT-exempt drugs Philippines, VAT exemption for diabetes and hypertension medicines, and VAT-exempt COVID-19 medicines Philippines.

How Ablola, Saribong & Gueco Can Help

RMC No. 68-2022 is especially important for companies in the healthcare, pharmaceutical, retail, distribution, and hospital sectors because a VAT classification error can affect pricing, billing, tax returns, and audit exposure across thousands of transactions. The issue is not simply whether a medicine treats a covered disease, but whether the taxpayer has properly documented and implemented the exemption at the product level.

Ablola, Saribong & Gueco assists businesses with BIR compliance, VAT classification reviews, tax audit preparation, invoicing and documentation controls, and legal opinions on the tax treatment of regulated products. For pharmacies, hospitals, distributors, importers, and corporate taxpayers dealing with VAT-exempt medicines under the CREATE Act, our team can help review product classifications, prepare compliance guidance, and address BIR audit risks. For assistance, visit MakatiLawFirm.com.

Leave a Comment

Your email address will not be published. Required fields are marked *